NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the New York State Department of Health has given the company's miRview lung assay final approval for marketing in the state.
A week-long power grab in the state Senate has left in limbo the future of the bill, which would award up to $3 million in tax credits to early-stage biotech companies that promise to relocate to or expand within the Big Apple.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
